Neovacs CEO outlines clinical timeline for lupus drug

November 24, 2016 Christoph Graener

Miguel Sieler, CEO of 25-year-old French vaccines company Neovacs, chats with Mike Ward, global director of content for Informa Pharma Intelligence, about the company’s early lead in immunostimulation research. They discuss upcoming clinical milestones for the company’s lead candidate IFNα-Kinoid—a drug targeting systemic lupus erythematosus—and innovative early-stage research Neovacs is pursuing in the Type 1 diabetes space. Founded in 1993 by the famous French immunologist Dr. Daniel Zagury, NeoVacs is a spin-off from the University Pierre et Marie Curie in Paris.

  

  

Interviewer: Mike Ward – Global Director of Content, Informa Pharma Insights
Interviewee: Miguel Sieler – CEO, Neovacs

Previous Article
Cinfa outlines biosimilar development areas and deal opportunities
Cinfa outlines biosimilar development areas and deal opportunities

Cinfa Biotech's managing director, Ruediger Jankowsky, discusses the company's founding and focus on biosim...

Next Article
Boehringer Ingelheim’s new R&D strategy focuses on external innovation
Boehringer Ingelheim’s new R&D strategy focuses on external innovation

"We are truly interested in innovative science no matter where it originates. Paving the way for business c...